Physician profile
Michael E Peterson
NPI 1336238757
$519.32
in general payments reported to CMS, 2019-2025
11 companies · $90.60 in 2025
The $90.60 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $59.06 · 2021: $85.68 · 2022: $163 · 2023: $56.34 · 2024: $65.04 · 2025: $90.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $211.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elekta, INC. | $163.03 | 2021-2022 | |
| Siemens Medical Solutions USA, INC. | $116.95 | 2022-2025 | Truebeam |
| Janssen Biotech, INC. | $66.96 | 2020-2024 | Darzalex, Talvey, Tecvayli |
| Novartis Pharmaceuticals Corporation | $52.27 | 2022-2024 | |
| Gilead Sciences, INC. | $23.88 | 2021-2022 | |
| Seagen INC. | $21.92 | 2022 | |
| Merck Sharp & Dohme LLC | $20.66 | 2023 | Keytruda |
| E.R. Squibb & Sons, L.L.C. | $17.77 | 2023 | Opdivo |
| Daiichi Sankyo INC. | $13.39 | 2024 | Enhertu |
| Blueprint Medicines Corporation | $11.50 | 2020 | |
| Celgene Corporation | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Peterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.